natgillin/translations-raw huggingface dataset:
Rimonabant 20 mg reduced the risk of weight regain. 
Rimonabant v odmerku 20 mg je zmanjšal tveganje za ponovno povečanje telesne mase.
These were usually mild or moderate in severity and resulted in recovery in all cases either after corrective treatment or discontinuation of rimonabant and did not exhibit any differentiating characteristics compared to cases reported in the control groups. 
Te motnje so bile ponavadi blage ali zmerne in so se v vseh primerih popravile (bodisi po korektivni terapiji ali prekinitvi rimonabanta) ter niso imele drugačnih značilnosti kot v kontrolnih skupinah.
Effects of rimonabant on pre- and post-natal development were assessed in the rat at doses up to 10 mg/kg/day. 
Vplive rimonabanta na pre- in postnatalni razvoj so raziskali pri podganah v odmerkih do 10 mg/kg/dan.
A similar increase in exposure is expected with other potent CYP3A4 inhibitors. 
Podobno povečanje izpostavljenosti je mogoče pričakovati z drugimi močnimi zaviralci CYP3A4.
The efficacy and safety of rimonabant treatment in patients over 75 years of age has not sufficiently been established. 
Učinkovitost in varnost zdravljenja z rimonabantom pri bolnikih, starejših od 75 let, nista dovolj raziskani.
The activity of ACOMPLIA is increased by simultaneous use of some drugs (so-called CYP3A4 inhibitors) such as: 
Delovanje zdravila ACOMPLIA se poveča, če hkrati uporabljate določena zdravila (t. i. zaviralce CYP3A4), npr.:
- You are advised to share the information in this leaflet with relatives or other relevant persons. 
- S podatki v tem navodilu seznanite svoje sorodnike ali druge osebe, ki skrbijo za vas.
Treatment should consist of the general measures employed in the management of overdoses, such as keeping airways unobstructed, monitoring cardiovascular function and general symptomatic and supportive measures. 
Zdravljenje mora obsegati splošne ukrepe, ki se uporabljajo pri prevelikem odmerjanju, npr. ohranitev prehodnih dihalnih poti, nadzorovanje srčno-žilnega delovanja ter splošne simptomatske in podporne ukrepe.
Gender: The pharmacokinetics of rimonabant are similar in female and male patients. 
Spol: Farmakokinetika rimonabanta je pri bolnicah in bolnikih podobna.
Very common (≥10%); Common (≥1, <10%); Uncommon (≥0.1, <1%); Rare (≥0.01, <0.1%); Very rare (<0.01%), Not known (cannot be estimated from the available data). 
Razvrstitev pričakovanih pogostnosti neželenih učinkov: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1,000 do < 1/100); redki (≥ 1/10,000 do < 1/1,000); zelo redki (< 1/10,000), neznani (ni mogoče oceniti iz razpoložljivih podatkov).
The following table (table 1) shows all treatment-emergent adverse reactions from placebo-controlled studies in patients treated for weight loss and related metabolic disorders when these incidences were statistically significantly greater than the corresponding placebo rate (for events ≥ 1%) or considered clinically relevant (for events < 1%). 
Naslednja tabela (tabela 1) prikazuje vse neželene učinke, ki so se pojavili med zdravljenjem v s placebom kontroliranih študijah, pri bolnikih zdravljenih za zmanjšanje telesne mase in zaradi sorodnih presnovnih motenj, če je bila njihova incidenca statistično značilno večja kot pri placebu (za dogodke ≥1%) ali so bile ocenjene kot klinično pomembne (za dogodke <1%).
− Nervous disorders: convulsions, disturbance in attention, headache. 
− bolezni živčevja: konvulzije, motnje pozornosti, glavobol.
Regarding reproductive parameters, at 30 mg/kg no differences were observed between treated animals and controls, at 60 mg/kg effects were still observed (decreased number of corpora lutea, implantations, total and viable fetuses). 
Kar zadeva reproduktivne parametre pri 30 mg/kg niso ugotovili razlik med zdravljenimi in kontrolnimi živalmi, pri 60 mg/kg so bili učinki še vedno opazni (zmanjšano število rumenih telesc, skupno število implantacij in plodov, sposobnih za življenje).
• Drug Interaction 
• Interakcije z zdravili
Animal data are inconclusive but suggest possible deleterious effects on embryonal/foetal development (see section 5.3). 
Podatki iz študij na živalih sicer niso zadostni, vendar nakazujejo možne škodljive vplive na razvoj zarodka oz. ploda (glejte poglavje 5.3).
− Psychiatric disorder: psychotic disorders including hallucinations, delusion and paranoia. 
− psihiatrična motnja: psihotične motnje vključno s halucinacijami, blodnjami in paranojo.
In obese patients, the elimination half-life is longer (about 16 days) than in non-obese patients (about 9 days) due to a larger volume of distribution. 
Pri debelih bolnikih je eliminacijski razpolovni čas zaradi večjega volumna porazdelitve daljši (okrog 16 dni) kot pri bolnikih, ki niso debeli (okrog 9 dni).
Concomitant administration of ketoconazole (a potent CYP3A4 inhibitor) increased rimonabant AUC by 104% (95% prediction interval: 40% - 197%). 
Sočasna uporaba ketokonazola (močnega zaviralca CYP3A4) je povečala AUC rimonabanta za 104% (95% napovedni interval: od 40% do 197%).
Do not use ACOMPLIA after the expiry date which is stated on the outer packaging after EXP. 
Zdravila ACOMPLIA ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na zunanji ovojnini poleg oznake "Upor.
The percentage of patients reaching HbA1c < 7% was 51% in the rimonabant group and 35% in the placebo group. 
HbA1c < 7 % je doseglo 51 % bolnikov, ki so dobivali rimonabant, in 35 % bolnikov, ki so dobivali placebo.
Patients with severe hepatic impairment were not evaluated. 
Bolnikov s hudo okvaro jeter niso ocenili.
Rimonabant should be used with caution in this population (see section 5.2). 
Rimonabant morate v tej populaciji uporabljati previdno (glejte poglavje 5.2).
This was confirmed clinically with specific probe studies using midazolam (CYP 3A4 substrate) and warfarin (CYP 2C9 substrate) and digoxin (a P-gp substrate). 
To so klinično potrdili s specifičnimi sondažnimi študijami z uporabo midazolama (substrat CYP3A4), varfarina (substrat CYP2C9) in digoksina (substrat P-gp).
Patients should be actively monitored for signs and symptoms of psychiatric disorders, particularly depression following the start of treatment. 
Po začetku zdravljenja je potrebno pri bolnikih aktivno spremljati znake in simptome psihiatričnih motenj, še posebej depresijo.
Population pharmacokinetic analysis indicated that rimonabant pharmacokinetics are similar between healthy non-smoking subjects and patients who smoke. 
Analiza populacijske farmakokinetike je pokazala, da je farmakokinetika rimonabanta pri zdravih nekadilcih podobna kot pri bolnikih, ki kadijo.
EXP {MM/YYYY} 
do: {MM/LLLL}
14 film-coated tablets 28 film-coated tablets 30 film-coated tablets 56 film-coated tablets 70x1 film coated-tablets 84 film-coated tablets 90 film-coated tablets 98 film-coated tablets 
14 filmsko obloženih tablet 28 filmsko obloženih tablet 30 filmsko obloženih tablet 56 filmsko obloženih tablet 70 x 1 filmsko obložena tableta 84 filmsko obloženih tablet 90 filmsko obloženih tablet 98 filmsko obloženih tablet
Since ACOMPLIA tablets contain lactose, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption, should not take this medicine. 
Tablete ACOMPLIA vsebujejo laktozo, zato bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze, ne smejo jemati tega zdravila.
ACOMPLIA 20 mg was effective in maintaining weight loss up to two years. 
ACOMPLIA 20 mg je učinkovito vzdrževala zmanjšano telesno maso do dve leti.
In the limited number of Black patients weight loss was less pronounced (mean difference to placebo -2.9 kg). 
Pri omejenem številu bolnikov črncev je bilo zmanjšanje telesne mase manj izrazito (povprečna razlika v primerjavi s placebom -2,9 kg).
Patients who had a cardiovascular event (myocardial infarction, stroke, etc.) less than 6 months ago were excluded in the studies for rimonabant. 
Bolniki, ki so pred manj kot 6 meseci doživeli srčno-žilni dogodek (miokardni infarkt, možgansko kap itn.), so bili izključeni iz študij z rimonabantom.
Patients had a BMI ≥ 30 kg/m² or BMI > 27 kg/m² with hypertension and/or dyslipidemia at inclusion. 
Bolniki so imeli ITM 30 kg/m2 ali ITM > 27 kg/m2 ter hipertenzijo in/ali dislipidemijo ob vključitvi.
Hypersensitivity to the active substance or to any of the excipients Lactation. 
Preobčutljivost za zdravilno učinkovino ali katerokoli pomožno snov.
Treatment with rimonabant was associated with significant reductions in waist circumference, a known marker of intra-abdominal fat. 
Zdravljenje z rimonabantom je spremljalo pomembno zmanjšanje obsega pasu, ki je znan kazalec intraabdominalnega maščevja.
Time to steady state is longer in obese patients (25 days) as a consequence of the higher volume of distribution in these patients. 
Čas do stanja dinamičnega ravnovesja je pri debelih bolnikih daljši (25 dni), ker je volumen porazdelitve pri njih večji.
The most common adverse reactions resulting in discontinuation were: nausea, mood alteration with depressive symptoms, depressive disorders, anxiety and dizziness. 
Najpogostejši neželeni učinki, ki so povzročili prekinitev, so bili: navzeja, spremembe razpoloženja z depresivnimi simptomi, depresivne motnje, anksioznost in omotica.
The apparent peripheral volume of distribution of rimonabant appears to be related to body weight, with obese patients having a higher volume of distribution than normal-weight subjects. 
Zdi se, da je navidezni periferni volumen porazdelitve rimonabanta povezan s telesno maso; debeli bolniki imajo večji volumen porazdelitve kot preiskovanci z normalno telesno maso.
− ritonavir (medicine for the treatment of HIV infections) 
− ritonavir (zdravilo za zdravljenje okužbe s HIV),
A direct effect of rimonabant cannot be ruled out. 
Neposrednega učinka rimonabanta ni mogoče izključiti.
The endocannabinoid system is a physiological system present in brain and peripheral tissues (including adipocytes) that affects energy balance, glucose and lipid metabolism and body weight, and in neurons of the mesolimbic system modulates the intake of highly palatable, sweet or fatty foods. 
Endokanabinoidni sistem je fiziološki sistem v možganih in perifernih tkivih (vključno z adipociti), ki vpliva na ravnovesje energije, presnovo glukoze in lipidov ter na telesno maso in ki v nevronih mezolimbičnega sistema modulira vnos zelo okusne, sladke ali mastne hrane.
Laboratory adverse events ACOMPLIA has not been shown to alter laboratory test values. 
Laboratorijski neželeni učinki Ni ugotovljeno, da bi ACOMPLIA spreminjala vrednosti laboratorijskih testov.
Data are insufficient to draw conclusions regarding pharmacokinetics in moderate hepatic impairment. 
Podatkov ni dovolj za sklepanje o farmakokinetiki pri zmerni okvari jeter.
− metabolism and nutrition disorders: anorexia, decreased appetite, 
− presnovne in prehranske motnje: anoreksija, zmanjšanje apetita
The MAH must ensure that the system of pharmacovigilance is in place and functioning before the product is placed on the market. 
Imetnik dovoljenja za promet mora zagotoviti vzpostavljen sistem vodenja farmakovigilance, ki mora delovati že pred prihodom zdravila na trg.
− if you are currently being treated for depression 
− če se trenutno zdravite zaradi depresije
− nefazodone (anti-depressor) 
− nefazodon (antidepresiv).
There was a treatment related increase in pup mortality in the pre-weaning period. 
Opažena je bila večja s terapijo povezana umrljivost mladičev podgan v obdobju pred odstavitvijo.
Administration of rimonabant to healthy subjects in the fasted state or with a high fat meal demonstrated that Cmax and AUC were increased 67% and 48% respectively, under fed conditions. 
Uporaba rimonabanta pri zdravih preiskovancih na tešče ali z zelo mastnim obrokom je pokazala, da je bila Cmax na poln želodec večja za 67 % in AUC za 48 %.
• Race 
• Rasa
You need to start and continue a reduced calorie diet and a physical activity program to get best results. 
Da boste dosegli najboljše uspehe, morate začeti in vzdrževati manj kalorično dieto in program telesne dejavnosti.
No convulsions were observed in dogs during a 3 month study. 
Med 3-mesečno študijo na psih konvulzij niso zabeležili.
This could be caused by a higher rimonabant clearance than in Caucasians resulting in a lower exposure (see section 5.2). 
Vzrok tega bi lahko bil večji očistek rimonabanta pri črncih kot pri belcih s posledično manjšo izpostavljenostjo (glejte poglavje 5.2).
Patients, especially those with a history of depressive disorders/mood alterations, (and relatives or other relevant persons) should be alerted about the need to monitor for the emergence of such symptoms and to seek medical advice immediately if these occur. 
Bolnike, še posebej tiste, ki so kdaj imeli depresivno/razpoloženjsko motnjo (in njihove sorodnike ali druge osebe, ki za njih skrbijo) je treba opozoriti, da morajo biti pozorni na pojav tovrstnih simptomov.
Following dosing for a longer treatment duration prior to mating (9 weeks) that permitted recovery from the initial effects of rimonabant, no adverse effects were seen on fertility or oestrous cyclicity. 
Po dolgotrajnejši uporabi pred parjenjem (9 tednov), ki je omogočila okrevanje po uvodnih vplivih rimonabanta, niso ugotovili neželenih učinkov na plodnost in cikličnost estrusa.
Potential for other medicinal products to affect rimonabant: 
Možnost vpliva drugih zdravil na rimonabant:
If you are intolerant to some sugars, contact your doctor before taking this medicine. 
Če ne prenesete nekaterih sladkorjev, se morate pred jemanjem tega zdravila posvetovati z zdravnikom.
The increased pup mortality might be attributable to a failure of the dam to nurse or ingestion of rimonabant in milk and/or inhibition of the suckling reflex that is reported in the literature to be initiated in neonatal mice by endocannabinoid signalling via CB1 receptors. 
Večjo umrljivost mladičev podgan je morda mogoče pripisati nezmožnosti samic za dojenje ali pa zaužitju rimonabanta z mlekom in/ali zavrtju sesalnega refleksa, za katerega je v literaturi opisano, da ga pri novoskotenih miših sproži endokanabinoidni prenos prek receptorjev CB1.
Monitoring of blood glucose level is recommended in these patients. 
Pri teh bolnikih je priporočljiv nadzor sladkorja v krvi.
Pharmaco-therapeutic group: Anti obesity agent ATC code: A08AX01 
Farmakoterapevtska skupina: Zaviralci apetita, brez dietnih pripravkov Oznaka ATC: A08AX01
Tablet polishing: carnauba wax (E903) 
Glazura tablete: karnauba vosek (E903)
Although concomitant administration of CYP3A4 inducers (e.g. rifampicin, phenytoin, phenobarbital, carbamazepine, St John's wort) has not been studied, it is expected that concomitant administration of potent CYP3A4 inducers may reduce the plasma concentration of rimonabant and may result in loss of efficacy. 
Sočasna uporaba induktorjev CYP3A4 (npr. rifampicina, fenitoina, fenobarbitala, karbamazepina, šentjanževke) sicer ni raziskana, a pričakovati je, da lahko sočasna uporaba močnih induktorjev CYP3A4 zmanjša koncentracijo rimonabanta v plazmi in tako zmanjša njegovo učinkovitost.
Subjects with a 10% weight reduction Difference (CI 95%) 
preiskovanci z 10 % zmanjšanjem telesne mase razlika (IZ95 %)
ACOMPLIA is contraindicated during breast-feeding (see section 4.3). 
ACOMPLIA je kontraindicirana med obdobjem dojenja (glejte poglavje 4.3).
If you take more ACOMPLIA than you should If you take more ACOMPLIA than you should tell a doctor or pharmacist. 
Če ste vzeli večji odmerek zdravila ACOMPLIA, kot bi smeli Če ste vzeli večji odmerek zdravila ACOMPLIA, kot bi smeli, morate to povedati zdravniku ali farmacevtu.
Generally ACOMPLIA 20 mg had no significant effect on Total-C or LDL-C levels. 
Na splošno ACOMPLIA 20 mg ni pomembno vplivala na koncentracijo celotnega holesterola ali holesterola LDL.
The potential for inhibition of CYP2C8 in vivo appears to be low. 
Kaže, da je potencial za zavrtje CYP2C8 in vivo majhen.
Rare side effects, that affect less than 1 per 1000, that have occurred in patients on ACOMPLIA include: hallucinations. 
Redki neželeni učinki, ki se pojavijo pri manj kot 1 od 1000 oseb in so bili zabeleženi pri bolnikih, ki so uporabljali zdravilo ACOMPLIA, vključujejo: halucinacije.
The pharmacokinetics and safety of rimonabant have not been studied in patients with severe hepatic impairment; its use in these patients is not recommended. 
Farmakokinetika in varnost rimonabanta nista raziskani pri bolnikih s hudo okvaro jeter; uporaba zdravila pri teh bolnikih zato ni priporočljiva.
Potential for rimonabant to affect other medicinal products: 
Možnost vpliva rimonabanta na druga zdravila:
Experience with rimonabant in overdosage is limited. 
Izkušnje s prevelikim odmerjanjem rimonabanta so omejene.
The tablets contain approx. 115 mg lactose. 
Tablete vsebujejo približno 115 mg laktoze.
Circulating metabolites do not contribute to its pharmacologic activity. 
Presnovki v obtoku ne prispevajo k njegovemu farmakološkemu delovanju.
• Lactose 
• Laktoza
Rimonabant has been detected in the milk of lactating rats and rimonabant may inhibit the suckling reflex. 
Rimonabant so našli v mleku doječih podgan in zdravilo lahko zavre sesalni refleks.
In clinical studies for other indications, the following additional adverse reactions were commonly reported: 
V kliničnih študijah pri drugih indikacijah so bili pogosto opisani naslednji dodatni neželeni učinki:
Please inform your doctor or pharmacist if you are taking or have recently taken the above mentioned medicines or any other medicines, including those obtained without a prescription such as St John's wort, rifampicin (antibiotic), medicines for weight loss, medicines to improve blood lipids (fats), antidiabetes medicines and medicines to treat epilepsy (e.g. phenytoin, phenobarbital, carbamazepine) or depression. 
Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta, npr. šentjanževko, rifampicin (antibiotik), zdravila za hujšanje, zdravila za izboljšanje lipidov (maščob) v krvi, zdravila proti diabetesu, zdravila proti epilepsiji (npr. fenitoin, fenobarbital, karbamazepin) ali zdravila proti depresiji.
Concomitant administration of orlistat, ethanol or lorazepam had no significant effect on the plasma levels of rimonabant. 
Sočasna uporaba orlistata, etanola ali lorazepama ni pomembno vplivala na koncentracijo rimonabanta v plazmi.
If you experience symptoms of depression (see below) during treatment with ACOMPLIA you should contact your doctor and stop the treatment. 
Če se med zdravljenjem z zdravilom ACOMPLIA pojavijo simptomi depresije (glejte spodaj), zdravilo ACOMPLIA prenehajte jemati in se posvetujte s svojim zdravnikom.
− if you have severely impaired renal function 
− če imate zelo okvarjeno delovanje ledvic,
Name and address of the manufacturers responsible for batch release Sanofi Winthrop Industrie, 30-36 Avenue Gustave Eiffel, BP 27166, F-37071 Tours Cedex 2, France sanofi-aventis S.p.A., Strada Statale 17, Km 22 , 67019 Scoppito (AQ), Italy The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch. 
(ODGOVORNI) ZA SPROŠČANJE SERIJE Ime in naslov izdelovalca (izdelovalcev), odgovornega (odgovornih) za sproščanje serije Sanofi Winthrop Industrie, 30-36 Avenue Gustave Eiffel, BP 27166, F-37071 Tours Cedex 2, Francija sanofi-aventis S.p.A., Strada Statale 17, Km 22, 67019 Scoppito (AQ), Italija V natisnjenem navodilu za uporabo zdravila mora biti navedeno ime in naslov izdelovalca, odgovornega za sproščanje zadevne serije.
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http://www.emea.europa.eu. 
Navodilo je bilo odobreno "Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMEA): http://www.emea.europa.eu/."
ACOMPLIA 20 mg nITT 
ACOMPLIA 20 mg nZNZ
Asthenia/fatigue Influenza 
Splošne težave astenija/ utrujenost gripa
Contact your doctor immediately if you become pregnant, think you might be pregnant or are planning to become pregnant while taking ACOMPLIA. 
Če med jemanjem zdravila ACOMPLIA zanosite, sumite, da ste zanosili, ali načrtujete nosečnost, se morate takoj posvetovati z zdravnikom.
Population pharmacokinetic analysis demonstrated less fluctuation in peak to trough plasma concentration but no differences in steady state AUC as weight increases. 
Analiza populacijske farmakokinetike ob povečevanju telesne mase je pokazala manj nihanja v razmerju med najvišjo in najnižjo koncentracijo v plazmi, a nobenih razlik v AUC v stanju dinamičnega ravnovesja.
Experience in patients over 75 years and Orientals/Asians was limited. 
Ni dovolj zkušenj pri bolnikih, starejših od 75 let in pri osebah orientalskega/azijskega porekla.
The effect of renal function on the pharmacokinetics of rimonabant has not been studied specifically. 
Učinek delovanja ledvic na farmakokinetiko rimonabanta ni posebej raziskan.
In the pre- and post-natal development study in rats, exposure to rimonabant in utero and via lactation produced no alterations on learning or memory, but equivocal effects on motor activity and auditory startle response were observed in the pups as a result of rimonabant exposure. 
V študiji pre- in postnatalnega razvoja pri podganah izpostavljenost rimonabantu in utero prek dojenja ni povzročila sprememb pri učenju ali pomnjenju, so pa pri mladičih podgan kot posledico izpostavljenosti rimonabantu opažali nejasne učinke na motorično delovanje in zdrznitev na slušni dražljaj.
Do not take this medicine when breast-feeding. 
Ne jemljite tega zdravila, če dojite.
No conclusions can be drawn with regard to effects in patients over 75 years or in Asian/Oriental patients due to the low number of patients. 
Zaradi majhnega števila bolnikov ni mogoče sklepati o učinkih pri bolnikih, starejših od 75 let, in pri bolnikih azijskega/orientalskega porekla.
In standard fertility studies in female rats (dosing for 2 weeks prior to mating) there was abnormal oestrous cyclicity and a decrease in corpora lutea and fertility index at doses of rimonabant that induced maternal toxicity (30 and 60 mg/kg/day). 
V standardnih študijah plodnosti na podganjih samicah (uporaba zdravila 2 tedna pred parjenjem) so ugotovili nenormalno cikličnost estrusa ter zmanjšanje rumenih telesc in indeksa plodnosti ob odmerkih rimonabanta, ki so povzročili toksične učinke pri samicah-materah (30 in 60 mg/kg/dan).
During post-marketing experience the following side effects have also been reported (frequency not known): 
Po prihodu zdravila na trg so poročali o naslednjih neželenih učinkih (pogostnost neznana):
The clinical effect (weight loss) of rimonabant in Black patients was lower than in Caucasians. 
Klinični učinek (zmanjšanje telesne mase) rimonabanta je bil pri črncih manjši kot pri belcih.
As an adjunct to diet and exercise for the treatment of obese patients (BMI ≥ 30 kg/m2), or overweight patients (BMI > 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1). 
Kot dodatek k dieti in telesni dejavnosti za zdravljenje debelih bolnikov (ITM ≥ 30 kg/m2), ali bolnikov s čezmerno telesno maso (ITM > 27 kg/m2) z enim ali dvema spremljajočima dejavnikoma tveganja, kot sta diabetes tipa 2 ali dislipidemija (glejte poglavje 5.1).
Due to the effect of rimonabant on the blood glucose level, when rimonabant is administered in diabetic patients, hypoglyceamia can occur (see section 4.8). 
Zaradi učinka rimonabanta na koncentracijo sladkorja v krvi, se lahko pri bolnikih s sladkorno boleznijo po zaužitju rimonabanta pojavi hipoglikemija (glejte poglavje 4.8).